With recent remarkable technological advances in radiation therapy, stereotactic body radiation therapy (SBRT) is regarded as an alternative treatment option for hepatocellular carcinoma (HCC) that is not suitable for curative treatment. Several prospective and retrospective studies on the use of SBRT in patients with HCC showed promising results. Furthermore, on-going prospective studies are examining the role of SBRT as a single ablative modality or a combination treatment in patients with HCC. Here, we summarize previous studies and recent updates and discuss the future perspectives of SBRT for HCC. (J Liver Cancer 2018;18:94-102)

Keywords: Carcinoma, Hepatocellular; Radiation

INTRODUCTION

With remarkable recent technological advances in radiation therapy, including four-dimensional computed tomography, intensity-modulated radiation therapy, image-guided radiation therapy (IGRT), and respiratory-gated delivery, stereotactic body radiation therapy (SBRT) has been regarded as an alternative treatment option for small hepatocellular carcinomas (HCCs) that are not suitable for hepatic resection and radiofrequency ablation (RFA).1-4 Recently, 2018 practice guidance by the American Association for the Study of Liver Disease suggested SBRT as one of alternative treatments to thermal ablation for the Barcelona Clinic Liver Cancer stage A patients.5 Here, we summarize previous studies and recent updates and discuss the future perspectives of SBRT for HCC.

DEFINITION OF SBRT

SBRT (also known as stereotactic ablative body radiation therapy [SABR]) is an external beam radiation therapy method used to deliver a high dose of radiation very precisely to an extracranial tumor, using a small number of fractions.6 The ability to deliver a few fractions of high-dose radiation with high targeting accuracy and rapid dose fall-off gradients outside the target region provides the basis for the development of SBRT.7

However, HCC presents challenges in imaging at simulation and at beam delivery because of the lack of inherent
contrast between the tumor and surrounding liver and respiratory motion. Because a normal liver itself as well as many critical normal organs surrounding the liver are radiosensitive, a comprehensive image guidance and motion management strategy are necessary to ensure safe and effective positioning for treatment. Therefore, SBRT practice, especially for HCC, requires a high level of confidence in terms of accuracy of the entire treatment procedure, and this confidence is achieved through the integration of modern imaging, simulation, treatment planning, and delivery technologies in all phases of the radiation therapy process. On the contrary, SBRT is not recommended if the extent of the tumor is uncertain or if large volumes of normal tissues need to be included within the radiation field to ensure sufficient coverage of microscopic tumor infiltration.

RESULTS OF PROSPECTIVE STUDIES

Several prospective studies on the use of SBRT in patients with HCC have been reported. Although the indications for SBRT vary among studies, most have shown promising results after SBRT for HCC (Table 1).

Tse et al. conducted a phase I study of SBRT for unresectable HCC (n=31) or intrahepatic cholangiocarcinoma (n=10) not suitable for standard therapies, and they reported a 1-year in-field local control rate of 65% and a median survival of 11.7 months for HCC. In the expanded phase I/II trial at the same institution, Bujold et al. reported a 1-year local control rate of 87% and a median overall survival of 17 months. In these two studies, an individualized six-fraction SBRT allowed large, multifocal tumors and HCC with major vascular thrombosis to be treated as opposed to most SBRT focusing on small HCC in other series. Nevertheless, SBRT can lead to sustained local control with a low incidence of serious toxicity in patients for whom curative local treatment options are not available. In another phase I/II study from North America, the authors reported 2-year local control and overall survival rates of 90% and 67%, respectively, and a median time-to-progression of 47.8 months in 60 patients with liver-confined HCC (median tumor diameter, 3.2 cm) at the time of SBRT.

Similarly, recent prospective trials conducted in Asian countries have also reported excellent clinical outcomes with SBRT for HCC. Kang et al. conducted a phase II trial of SBRT as a local salvage treatment after incomplete transarterial chemoembolization (TACE) in patients with HCC. They included single or multiple lesions, even with vascular invasion, and a maximum tumor diameter of <10 cm for salvage SBRT; they reported a 2-year local control rate of 94.6% in patients with incomplete TACE for inoperable HCC. Take-da et al. also conducted a phase II study of SBRT for early stage or small HCC with curative intent. Among the included patients, 32 (36%) were treatment naïve and 18 had HCC that measured ≥3 cm at its greatest dimension (maximum tumor dimension, ≥4 cm). They also reported a 3-year local control rate of 96.3% and a 3-year liver-related cause-specific survival rate of 72.5% and concluded that SBRT achieved high local control and overall survival rates for patients with solitary HCC in treatment-naïve, intrahepatic failure, residual disease, and recurrent settings.

One recent phase II study revealed that patients who underwent individualized adaptive therapy, i.e., patients received 3 of 5 planned SBRT treatments, waited 4 weeks for potential subclinical liver function change and then underwent repeat assessment of the indocyanine green 15, and the radiation dose for the final 2 treatments was then adjusted. This approach can be used to achieve both high rates of local control (2-year local control rates of 95%) and a high degree of safety.

RETROSPECTIVE STUDY RESULTS

In addition to early phase prospective trials, many retrospective studies have examined SBRT for HCC, and studies involving >50 patients are summarized in Table 1. Jang et al. reported a dose-response relationship in 108 patients (122 lesions) with HCC who were treated with 3-fraction SBRT. The median longest tumor diameter was 3 cm (range, 1-7 cm), and the median prescribed dose was 51 Gy (range, 33-60 Gy). They divided the dose group as follows: >54 Gy, 45-54 Gy, and <45 Gy and reported 2-year local control rates of 100%, 78%, and 64%, respectively (P=0.009). In contrast,
| Study | Design | No. of pts. | No. of HCC | PVTT | Extrahepatic | Tumor size, median (range) (cm) | CP class | Dose prescription, median (range), Gy/fractions | LC (%) | OS (%) |
|-------|--------|-------------|------------|------|--------------|-------------------------------|----------|-----------------------------------------------|--------|--------|
| Tse et al (2008) | Phase I | 31 | 1 | Yes, 52% | Yes, 9% | 173 mL (9-1913 mL) | A | 36/6 (24-54) | 65 (1 Y) | 48 (1 Y) |
| Andolino et al (2011) | Phase VII | 60 | 1-3 | NA | No | 3.1 (1.0-6.5) | A,B | CP-A: 44/3 (30-48) CP-B: 40/5 (24-48) | 90 (2 Y) | 67 (2 Y) |
| Kang et al (2012) | Phase II | 47 | 1-3 | Yes, 11% | No | 2.9 (1.3-7.8) (sum of size) | A,B | 57/3 (42-60/3) | 95 (2 Y) | 69 (2 Y) |
| Bujoj et al (2013) | Phase VII | 102 | NA | Yes, 55% | Yes, 12% | 7.2 (1.4-23.1) | A | 24-54/6 | 87 (1 Y) | 55 (1 Y) |
| Takeda et al (2016) | Phase II | 90 | 1 | NA | No | 2.3 (1.0-4.0) | A,B | 35/5 or 40/5 | 96 (3 Y) | 67 (3 Y) |
| Feng et al (2017) | Phase II | 69 | 1-4 | Yes, 18% | NA | 3 (0-13.0) (all) | A,B | 49 (23-60/3-5) | 99 (1 Y) | NA |
| Yoon et al (2013) & Jung et al (2013) | Retro | 93 | 1-2 | No | No | 2 (1.0-6.0) | A,B | 45/3 (30-60/3-4) | 95 (1 Y) | 86 (1 Y) |
| Jang et al (2011) | Retro | 82 | 1-3 | Yes, 10% | NA | 3.0 (1.0-7.0) | A,B | 51/3 (33-60/3) | 87 (2 Y) | 63 (2 Y) |
| Bibault et al (2013) | Retro | 75 | 1-3 | NA | No | 3.7 (3.0-4.4) | A,B | 45/3 (24-45/3) | 90 (1 Y) | 79 (1 Y) |
| Yamashita et al (2014) | Retro | 79 | 1 | NA | NA | 2.7 (0.6-7.0) | A,B,C | 48/4 (40-60/4-10) | 75 (2 Y) | 53 (2 Y) |
| Sanuki et al (2014) | Retro | 185 | 1 | NA | No | 35 Gy group: 2.7 (1.0-5.0) 40 Gy group: 2.4 (0.5-5.0) | A,B | CP-A: 40/5 CP-B: 35/5 | 99 (1 Y) | 95 (1 Y) |
| Takeda et al (2014) | Retro | 63 | 1 | NA | No | 2.6 (1.0-5.0) | A,B | CP-A: 40/5 CP-B: 35/5 | 100 (1 Y) | 100 (1 Y) |
| Wahl et al (2015) | Retro | 63 | 1-4 | NA | NA | 2.2 (0-10) | A,B,C10 | 30 or 50 (27-60/3-5) | 97 (1 Y) | 74 (1 Y) |
| Huertas et al (2015) | Retro | 77 | 1-3 | NA | No | 2.4 (0.7-6.3) | A,B | 45/3 | 99 (1 Y) | 82 (1 Y) |
| Su et al (2015) | Retro | 132 | NA | NA | NA | 3.0 (1.1-5.0) | A,B | 42-46/3-5, 28-30/1 | 91 (1 Y) | 74 (1 Y) |
| Kimura et al (2015) & Kubo et al (2017) | Retro | 65 | 1-2 | No | No | 1.6 (0.5-5.4) | A,B | 48/4 | 100 (3 Y) | 56 (3 Y) |
| Lo et al (2017) | Retro | 89 | NA | Yes, 49% | Yes, 29% | 6.2 (1.2-18.5) | A,B | 45 (25-60/4-6) | 78 (3 Y) | 46 (1 Y) |
| Jeong et al (2018) | Retro | 119 | NA | No | No | 1.7 (0.8-6.0) | A,B | 45/3 (30-60/3-4) | 99 (1 Y) | 99 (1 Y) |

SBRT, stereotactic body radiation therapy; pts, patients; HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombus; CP, Child-Pugh; Gy, Gray; LC, local control; OS, overall survival; Y, year; CC, cholangiocarcinoma; NA, not available; Retro, retrospective.
Sanuki et al.\textsuperscript{18} evaluated local control rates according to two different prescription dose schedules in relatively large numbers of patients. In their analysis, they restricted the maximum tumor size to $\geq 5$ cm (range, 0.8-5 cm) and reported no difference in 3-year local control rates between the two groups (91\% in the 35 Gy/5-fraction group vs. 89\% in the 40 Gy/5-fraction group, $P=0.99$).\textsuperscript{18} Because both prescribed dose and tumor size can affect the local control rate after SBRT, a more well-designed study is required to determine the optimal prescribed dose to maximize tumor control without increasing the risks for hepatic toxicity following high-dose radiation therapy.

Other recent retrospective studies revealed that SBRT for small HCC can yield excellent local control rates (range, 84.1-100\%) and favorable overall survival outcomes (range, 50.4-81.9\% at 2 years).\textsuperscript{18-23} However, SBRT has been used as a salvage treatment following various locoregional treatments in most previously reported studies; therefore, it is difficult to directly compare overall survival rates between SBRT and other curative treatments, such as hepatic resection or RFA.\textsuperscript{19} Jeong et al.\textsuperscript{24} recently published excellent local control and overall survival rates (97.0\% and 83.8\% at 3 years, respectively) using a highly sophisticated radiation therapy technique, including IGRT. Therefore, evolution in radiation therapy techniques can also contribute to better clinical outcomes in the management of small HCC.

Wahl et al.\textsuperscript{25} conducted a retrospective comparison study between RFA ($n=161$) and SBRT ($n=63$) for inoperable and non-metastatic HCC from 2004 to 2012. They reported no significant difference of freedom from local progression between the two groups.

\textbf{Figure 1.} An example of good response of HCC after SBRT. The patient who had a 1.8 cm HCC in segment II (A: arterial phase, B: portal phase) received 45 Gy in three fractions of SBRT (C, D). This tumor disappeared on follow-up CT images with the background radiation-induced parenchymal change around the tumor at 3 months after SBRT (E: arterial phase, F: portal phase). HCC, hepatocellular carcinoma; SBRT, stereotactic body radiation therapy; Gy, Gray; CT, computed tomography.
| Study                        | Upper GI                          | Constraints                                                                 | Liver                                                                                     | Toxicity                                                                 | Gl | Other (rib, biliary, …) |
|-----------------------------|-----------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|----|------------------------|
| Tse et al (2008)            | 0.5 mL of esophagus, stomach, duodenum, or bowel <30 Gy | Normal liver >600 mL                                                        | RILD G3: 26% CP class change A→B: 16%                                                     | Tumor-duodenal connection: 3%                                             |    | Right-sided pleural effusion: 10% |
| Andolino et al (2011)       | $D_{max}$ of small bowel <12 Gy   | CP-A: 1/3 of normal liver ≤10 Gy; $V_{10Gy} ≥500$ mL CP-B: 1/3 of normal liver ≤18 Gy; $V_{18Gy} ≥500$ mL | CP class change: 20% (A→B: 12%; B→A: 8%); Hepatic failure: 7% (all with a CP score ≥8) | No GI toxicity ≥G3                                                      |    | No other toxicity ≥G3       |
| Kang et al (2012)           | GI constraints were not considered | $V_{10Gy} ≥700$ mL                                                         | No RILD CP class change A→B: 13%                                                         | GI toxicity G3: 6%                                                       |    | NA                     |
| Bujold et al (2013)         | $D_{max}$ of stomach, duodenum, small bowel, and large bowel <32, 33, 34, and 36 Gy | Normal liver >700 mL                                                        | RILD G2: 2% Worsening of CP score ≥1.9%                                                   | No GI toxicity                                                         |    | NA                     |
| Takeda et al (2016)         | Stomach, bowel <25 Gy             | $V_{20Gy} <20%$ of normal liver                                             | No RILD CP class change A→B: 13%                                                         | GI toxicity G3: 6%                                                       |    | NA                     |
| Feng et al (2017)           | 0.5 mL of stomach, duodenum <27.5 Gy, 30 Gy | ICG15 <44%                                                                  | No RILD CP class change A→B: 13%                                                         | GI toxicity G3: 6%                                                       |    | NA                     |
| Yoon et al (2013) & Jung et al (2013) | >2 cm from stomach, duodenum; 2 mL of stomach or duodenum <18 Gy; 2 mL of esophagus or large bowel <21 Gy | Normal liver >700 mL; $V_{15Gy} >700$ mL mean dose of normal liver <13 Gy | RILD ≥G2: 18% (≥G3: 7%); Worsening of CP score ≥2: 10% | No bleeding or perforation                                              |    | NA                     |
| Jang et al (2013)           | Esophagus: $D_{max} <24$ Gy; other GI constraints were not considered | $V_{15Gy} >700$ mL                                                         | RILD: 7%                                                                                   | Gastrroduodenal ulcer: 2%; perforation: 2%; colonic ulcer: 1%            |    | NA                     |
| Bibault et al (2013)        | 0.5 mL of stomach, duodenum, small intestine <25 Gy, 24 Gy, 27 Gy | $V_{10Gy} >700$ mL; $V_{5Gy} <50$%, $\gamma_{5Gy}$ | Liver decompensated ascites: 7%; Gastric ulcer G3: 1%, G4: 1%; Duodenal ulcer G2: 4%     | No other toxicity                                                       |    | NA                     |
| Sanuki et al (2014)         | Bowel <25 Gy                       | $V_{20Gy} <20%$ of normal liver                                             | Worsening of CP score ≥2: 10%; G5 hepatic failure: 1%                                   | NA                                                                      |    | NA                     |
| Takeda et al (2014)         | >2 cm from GI tract                | $V_{20Gy} <20%$ of normal liver                                             | RILD G3: 2%                                                                               | No GI toxicity                                                          |    | No other toxicity         |
| Wahl et al (2015)           | 0.5 mL of stomach, duodenum <22.5 Gy, 24 Gy | NA                                                                           | RILD: 2%                                                                                  | GI toxicity ≥late G3: 8.3%; biliary toxicity ≥late G3: 3%                |    | NA                     |
| Huertas et al (2015)        | Stomach: $D_{max} <24$ Gy, $D_{mean} <24$ Gy, $V_{15Gy} <5$ mL | $D_{2Gy} <21$ Gy, $D_{9Gy} <15$ Gy                                         | RILD G9%                                                                                  | Gastric ulcer G3: 1%; G4: 1%; Colic ulcer G2: 1%                       |    | NA                     |
| Su et al (2015)             | 1 mL of duodenum and stomach <25 Gy/5-5 fx, <15 Gy/1 fx | 3–5 fx; $V_{15Gy} >700$ mL; $V_{9Gy} <1/3$ total liver volume 1 fx; $V_{15Gy} >700$ mL; $V_{9Gy} <1/3$ total liver volume | G5 hepatic failure: 3%; Hepatic encephalopathy ≥G3: 2%; Upper GI hemorrhage ≥G3: 3% | No RILD CP class change A→B: 13%                                         |    | NA                     |
| Kimura et al (2015) & Kubo et al (2017) | 21 mL of GI tract <30 Gy/4 fx | NA                                                                           | RILD G3: 12%                                                                              | No ≥G3                                                                  |    | BD stricture G2: 2%; G3: 0%    |
| Lo et al (2017)             | NA                                | Normal liver >700 mL                                                        | RILD: 11%; fatal RILD: 2%; Worsening of CP score ≥2: 13%                                 | Gastric ulcer G3: 2%                                                   |    | NA                     |
| Jeong et al (2018)          | >2 cm from stomach, duodenum; 2 mL of stomach or duodenum <18 Gy; 2 mL of esophagus or large bowel <21 Gy | Normal liver >700 mL; $V_{15Gy} >700$ mL mean dose of normal liver <13 Gy | RILD ≥G2: 8% (G3: 2%); Worsening of CP score ≥2: 6%                                     | No bleeding or perforation                                              |    | NA                     |

GI, gastrointestinal; Gy, Gray; RILD, radiation-induced liver disease; CP, Child-Pugh; $D_{max}$, maximum dose; $V_{aGy}$, total volume-volume receiving certain of a Gy; G, grade; NA, not available; HCC, hepatocellular carcinoma; BD, bile duct; $V_{aGy}$, volume receiving certain of a Gy; ICGR, indocyanine green retention rate; CC, cholangiocarcinoma; fx, fraction.
between the two modalities, however, SBRT was associated with improved local control compared with RFA for HCC ≥2 cm. Although both treatment modalities are complementary to each other according to tumor location and accessibility, SBRT can also play a role as an ablative treatment option in the management of HCC. Fig. 1 shows a representative case of HCC who achieved complete response after SBRT.

**SBRT–RELATED TOXICITY**

1. Hepatic toxicity

Radiation-induced hepatic toxicity can occur after SBRT because the normal liver is a radiosensitive organ. Because most HCCs occur with a background of chronic liver disease, including viral hepatitis, non-classic radiation-induced liver disease (RILD) (elevation in liver transaminases or worsening of Child-Pugh score by ≥2) usually occurs within 3 months after completion of SBRT in the absence of classic RILD (elevated alkaline phosphatase level). The incidence of hepatic toxicity varies between studies (range, 2-13%) using different dose constraints for normal liver (Table 2). However, most patients showed improved or stable hepatic function with supportive care during the follow-up period, and the occurrence of fatal hepatic toxicities after SBRT is rare. According to baseline liver function before SBRT, the incidence of hepatic toxicity could increase in patients with Child-Pugh class B hepatic function; therefore, a more conservative dose prescription may be required for patients with liver function of Child-Pugh class B.

**Figure 2.** Examples of complications following SBRT: (A) biliary stricture at 13 months after SBRT; (B) rib fracture at 19 months after SBRT; (C) radiation pneumonitis at 6 months after SBRT. SBRT, stereotactic body radiation therapy.
2. Gastrointestinal toxicity

Gastrointestinal luminal structures, such as the stomach, duodenum, or large bowel are also radiosensitive organs in SBRT for HCC, if the tumor is located adjacent to these organs. Despite more accurate targeting ability using recently advanced radiation therapy technology, a sufficient safety margin between the tumor and these gastrointestinal structures remain necessary to reduce serious complications, including bleeding or perforation. According to the previous studies, the overall incidence of gastrointestinal toxicity is relatively low (range, 0-8.3%) (Table 2); nonetheless, most toxicities are severe and required recovery in intensive care. Because most patients have underlying liver cirrhosis, portal hypertension, and coagulopathy that can exacerbate the risk for gastrointestinal toxicities, care should be taken to review the proximity to critical normal organs that are highly sensitive to radiation prior to considering SBRT for HCC.

3. Other toxicity

The most frequent constitutional symptoms related to SBRT are fatigue, anorexia, and nausea; however, most symptoms are mild and recovered well without additional supportive care. If a tumor is in a central area, there is a chance to develop biliary stricture owing to hepatic fibrosis after SBRT. However, the incidence of this complication is also very low (2-3%). Radiation pneumonitis can occur in the right lower lung field if HCC is located near the diaphragm; however, most observed as radiographic changes with no accompanying symptoms. Some patients experience rib fractures or soft tissue toxicities after SBRT for peripheral tumors; nevertheless, most patients do not require any specific treatment (Table 2). Fig. 2 shows representative cases of biliary stricture, rib fracture, and radiation pneumonitis following SBRT.

ON-GOING CLINICAL TRIALS

There are many on-going prospective, single-arm, phase I or II studies regarding the role of SBRT in patients with HCC. In these trials, SBRT is used as a single ablative modality or as a combination treatment with TACE or systemic therapies. Moreover, there are many prospective randomized trials that aim to compare SBRT with other modalities or to define the use of SBRT in combination with other treatment modalities.

Table 3. On-going randomized trials

| Trial identifier | Patient population | Modalities | Primary outcome |
|------------------|--------------------|------------|----------------|
| NCT03172559      | Bridge to liver transplant in HCC | SBRT vs. no intervention | Proportion of participants that get to be transplanted |
| NCT02182687      | Bridge to liver transplant in HCC | SBRT vs. TACE | Time to first additional intervention to the treated lesions |
| NCT01963429      | Recurrent small HCC | PBT vs. RFA | Local progression free survival |
| NCT02323360      | Incomplete TACE | SBRT vs. TACE | Local tumor control |
| NCT03338647      | Advanced HCC | SBRT vs. TACE | Progression (total of local, intra- and extrahepatic) |
| NCT01730937      | Advanced or recurrent HCC | Sorafenib +/- SBRT | Overall survival |
| NCT03168152      | Localized HCC | SBRT vs. MWA | Time to local tumor progression |
| NCT02470533      | HCC ineligible for surgery or RFA | SBRT vs. DEB-TACE | Time to progression |
| NCT02762266      | Residual or recurrent HCC after TACE | SBRT vs. TACE | Freedom from local progression |
| NCT03079778      | HCC ineligible for surgery | TACE +/- SBRT | Time-to-intrahepatic-progression |
| NCT02794337      | Unresectable HCC | DEB-TACE +/- SBRT | In-field progression free survival |

HCC, hepatocellular carcinoma; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; PBT, proton beam therapy; RFA, radiofrequency ablation; MWA, microwave ablation; DEB, drug-eluting beads.
(Table 3). All these results are likely to provide more reliable answers on the use of SBRT in the management of HCC.

CONCLUSIONS

Based on results of early phase trials and retrospective series, SBRT is a safe and effective treatment modality for patients with HCC. SBRT can be a good alternative treatment for patients with small HCCs that are unsuitable for hepatic resection or local ablative therapy. A more definite role for SBRT in HCC may be identified from results of on-going prospective trials.

AUTHOR CONTRIBUTIONS

J Jung and SM Yoon are responsible for the acquisition of the data and drafting of the manuscript.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

REFERENCES

1. Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108:ddw133.
2. Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J 2016;34:160-167.
3. Citrin DE. Recent developments in radiotherapy. N Engl J Med 2017;377:1065-1075.
4. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015;16:465-522.
5. Marrero JA, Kulik LM, Sirlin C, Zhu AX, Finn RS, Abecassiss MM, et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-750.
6. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-332.
7. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004;60:1026-1032.
8. Brock KK. Imaging and image-guided radiation therapy in liver cancer. Semin Radiat Oncol 2011;21:247-255.
9. Solberg TD, Balter JM, Benedict SH, Fraass BA, Kavanagh B, Miyamoto C, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: executive summary. Pract Radiat Oncol 2012;2:2-9.
10. Benedikt SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37:4078-4010.
11. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008;26:657-664.
12. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 2013;31:1631-1639.
13. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011;81:e447-e453.
14. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-5431.
15. Takeda A, Sanuki N, Tsurugai Y, Ibuchi S, Matsuura K, Ebiruma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 2016;122:2041-2049.
16. Feng M, Suresh K, Schipper MJ, Bazzi L, Ben-Josef E, Matuszak MM, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. JAMA Oncol 2018;4:40-47.
17. Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, et al. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma. Radiat Oncol 2013;8:250.
18. Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-404.
19. Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma: results from a phase I study. J Clin Oncol 2011;29:3194-3199.
cellular carcinoma. PLoS One 2013;8:e79854.
20. Bibault JE, Dewas S, Vautravers-Dewas C, Hollebecque A, Jarraha H, Lacornerie T, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One 2013;8:e77472.
21. Kimura T, Aikata H, Takahashi S, Takahashi I, Nishibuchi I, Doi Y, et al. Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. Hepatol Res 2015;45:378-386.
22. Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, et al. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol 2015;115:211-216.
23. Su TS, Liang P, Lu HZ, Liang J, Gao YC, Zhou Y, et al. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. J Surg Oncol 2016;113:181-187.
24. Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, et al. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer 2018;18:416.
25. Wahl DR, Stenmark MH, Tao Y, Pollom EL, Cailli EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 2016;34:452-459.
26. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S94-S100.
27. Méndez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol 2006;45:831-837.
28. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, et al. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 2010;12:218-225.
29. Jung J, Yoon SM, Kim SY, Cho B, Park JH, Kim SS, et al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 2013;8:249.
30. Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, et al. Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 2014;111:412-417.
31. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); [cited 2018 Apr 25]. Available from: https://clinicaltrials.gov.
32. Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsu Y, Nomiy T, et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol 2014;9:112.
33. Takeda A, Sanuki N, Eriuguchi T, Kobayashi T, Iwabutchi S, Matsu T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:372-379.
34. Kubo K, Kimura T, Aikata H, Takahashi S, Takeuchi Y, Takahashi I, et al. Long-term outcome of stereotactic body radiotherapy for patients with small hepatocellular carcinoma. Hepatol Res 2018;48:701-707.
35. Lo CH, Yang JF, Liu MY, Jen YM, Lin CS, Chao HL, et al. Survival and prognostic factors for patients with advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One 2017;12:e0177793.